Replies to post #4431 on Phio Pharmaceuticals Corp (PHIO)

[sabaidii2]

Today's press release says RXI-185 (reducing skin laxity) now has a topical formulation that doesn't require micro needling (if I'm reading correctly).

This is a big deal. So much so, that I'm now less pissed off about the RXI-231 consumer testing delay.